U.S. Physical Therapy (USPH) Q2 2026 earnings review
Record Volumes Eclipsed by Margin Compression
U.S. Physical Therapy reported strong top-line growth of 8.5% driven by all-time high patient visits, but profitability failed to follow. Adjusted EBITDA was effectively flat year-over-year at $27.0 million, and Operating EPS declined from $0.81 to $0.75. The core issue lies in the Physical Therapy segment, where adjusted margins compressed 150 basis points despite record daily clinic volumes and higher reimbursement rates. Management reaffirmed their $102-$106 million full-year Adjusted EBITDA guidance, betting heavily on the back-half integration of newly acquired hospital affiliations and tech-driven cost savings. Hitting this target requires a significant sequential margin acceleration.
🐂 Bull Case
Demand remains exceptional. The company hit an all-time record of 33.5 average daily visits per clinic, while maintaining strong pricing power with net rates rising to $107.59 per visit.
The integration of 31 hospital-affiliated clinics was completed in Q2, with 39 more slated for Q3. These high-volume partnerships are expected to materially accelerate revenue and EBITDA margins in the back half of the year.
🐻 Bear Case
Record high clinic productivity typically drives significant margin expansion, but PT adjusted gross margins actually shrank from 21.4% to 19.9%, underscoring severe operating cost pressures.
With $47.2M in H1 Adjusted EBITDA, the company needs to generate ~$56.8M in H2 to hit its guidance midpoint. This requires flawless execution of clinic integrations and immediate realization of tech efficiencies.
⚖️ Verdict: ⚪
Neutral. Top-line execution is flawless, but the inability to convert record clinic density into higher margins is a red flag. The reaffirmed guidance is heavily back-end weighted and reliant on perfect integration execution.
Key Themes
Physical Therapy Margin Compression
Decelerating. Core Physical Therapy adjusted gross margins dropped from 21.4% in 25Q2 to 19.9% in 26Q2. This directly contradicts the narrative that higher volumes (record 33.5 visits/day) naturally expand margins via operating leverage. Management attributed roughly 100 basis points of this compression to an unfavorable impact from company-provided health benefit costs, alongside rising salaries as a percentage of revenue (up to 57.5% from 56.4%).
Record Clinic Productivity & Pricing
Accelerating. Patient demand continues to surge. The average daily visits per clinic reached 33.5, up from 32.7 a year ago. Concurrently, the net revenue per patient visit increased $2.26 YoY to $107.59. Sustaining volume growth alongside price increases proves the strength of USPH's clinical reputation and successful commercial rate negotiations.
Hospital Affiliation Integrations Underway
Accelerating. Management explicitly identified large hospital system affiliations as the primary growth driver for 2026. The integration of 31 clinics into the NYU alliance was completed in Q2, with the remaining 39 clinics expected to finalize in Q3. These chunky additions are meant to act as an immediate accelerant for back-half and 2027 earnings.
Macro Backdrop: Wage and Benefit Cost Inflation
Decelerating. The broader healthcare macro environment continues to pressure operations via elevated staffing and benefit costs. Salaries and related costs outpaced revenue growth, and the spike in company-provided health benefits severely restricted the bottom line. Unless the company successfully offsets this with technological efficiencies, unit economics will continue to erode.
Technology Implementation to Combat Labor Costs
Stable. In response to margin pressure, USPH is heavily leaning into tech efficiencies. The partial virtualization of front-desk processes and the rollout of AI-powered ambient listening for clinical documentation are actively being implemented. Management expects these specific initiatives to reduce labor dependence and drive margin recovery in the second half of 2026.
Aggressive Share Repurchases Mid-Guidance Ramp
During Q2, the company repurchased 306,256 shares for $19.2 million at an average price of $62.80. While this demonstrates confidence in the stock's valuation, it temporarily diverts capital away from their stated top priority of M&A, specifically in the high-growth IIP segment, during a quarter where debt levels increased to $221 million.
Other KPIs
Stable. IIP revenue grew 9.1% overall and 3.6% organically. Margins remained highly stable at 20.4% compared to 20.3% last year. While the growth rate has moderated from the blistering >20% pace seen in mid-2025, it remains a reliable, high-margin anchor for the company.
Decelerating. GAAP EPS cratered from $0.58 in 25Q2 down to $0.25. This massive spread between GAAP EPS and Operating EPS ($0.75) is primarily driven by changes in the value of redeemable non-controlling interests. Ironically, this charge reflects strong performance by minority partners increasing the buyout value of their stakes, heavily diluting GAAP metrics.
Stable. Corporate overhead scaled perfectly with revenue, remaining flat at 8.9% (GAAP) compared to the prior year, highlighting decent cost containment at the home-office level despite ongoing integration and ERP rollout efforts.
Guidance
Accelerating requirement. Management reaffirmed this full-year target. Having generated $47.2 million in H1, the company implies generating roughly $56.8 million in H2 (a ~20% sequential acceleration vs H1). This requires the hospital affiliations and tech rollouts to yield immediate and profound operating leverage.
Key Questions
Structural vs Temporary Margin Pressures
You attributed ~100 basis points of PT margin compression to company-provided health benefits. Is this a permanent step-up in the cost base, or are there specific mitigation strategies planned to reverse this headwind in 2027?
Hospital Affiliation Ramp Trajectory
Given the steep H2 Adjusted EBITDA implied by your reaffirmed guidance, how much of that back-half lift is strictly reliant on the remaining 39 hospital clinics integrating smoothly in Q3, versus organic tech-driven cost savings?
Capital Allocation Priority Shift
You deployed nearly $20 million toward share buybacks in Q2 while expanding the credit facility. Has there been a strategic pivot away from aggressively acquiring IIP assets, or were valuations in the private market temporarily unattractive?